GSK's Linerixibat MAA Accepted By EMA For PBC-Associated Itch
(RTTNews) - GSK plc (GSK), Monday confirmed that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational ileal bile acid transporter inhibitor, to treat cholestatic pruritus in primary biliary cholangitis. The submiss
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief